Vesugen

also known as: KED tripeptide, Lys-Glu-Asp, Vascular tripeptide

The synthetic KED tripeptide in the Khavinson short-peptide series, studied preclinically for vascular-aging and antiatherogenic effects. Not a registered medicine; research-only in the West, nutraceutical status in Russia. Preclinical evidence only.

A synthetic Lys-Glu-Asp (KED) tripeptide in the Khavinson short-peptide series, studied in a small preclinical literature for anti-atherogenic and vascular-protective effects. Reported to modulate endothelial gene expression in cell culture and to reduce aortic atherosclerotic lesion burden in aged rodent models in Khavinson-group publications. Research-only and nutraceutical-grade; no registered-medicine status, no human clinical trials, no independent Western replication.

Mechanism of action

Proposed to modulate vascular endothelial gene expression via the Khavinson-framework short-peptide-DNA-interaction hypothesis, with downstream effects on endothelial nitric oxide synthase (eNOS), adhesion molecule expression, and smooth-muscle proliferation. Preclinical models (rat aortic atherosclerosis, endothelial cell culture) have been reported to show antiatherogenic effects in Khavinson-group publications. Mechanism remains insufficiently characterized at molecular-target resolution.

Primary uses

Vascular aging research (preclinical)
Antiatherogenic research (preclinical rodent models)

Typical dosing

Not established for human use

⚠ No human dosing established. Rodent studies have used ~2–10 μg/kg peritoneal or subcutaneous. Any human use would be unregulated and unsupported.

Regulatory status

Not FDA- or EMA-approved. Sold as a research chemical in grey-market catalogs and as a nutraceutical supplement in Russia.

References

[pubmed] Khavinson VK, et al. "Peptide KED reduces experimental atherosclerosis in rats." Bull Exp Biol Med, 2013;155:810-812.
[review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149.

Related peptides

Ventfort

The Khavinson vascular bioregulator, marketed in Russia for endothelial aging and microcirculation support. Associated with the synthetic KEDG tetrapeptide in some Khavinson-group publications. Russian-language evidence base only; not FDA/EMA approved.

Cardiogen

A Khavinson-group tetrapeptide from heart-tissue extract — proposed to support cardiomyocyte function and cardiac tissue aging; evidence base is Russian-language and largely pre-clinical.

Epithalon

A synthetic pineal tetrapeptide from the Khavinson group (St. Petersburg) — the only peptide with published data claiming telomerase activation and telomere elongation in human cell models.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.